AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

AUAUniversity

Contenuto fornito da AUAUniversity and American Urological Association. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da AUAUniversity and American Urological Association o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

6M ago 1:56:16

MP3•Pagina principale dell'episodio

AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider CME Available: https://auau.auanet.org/node/41015 At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB) 2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists. 3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents 5. Discuss potential future pharmacological pathways and therapies for OAB. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas

360 episodi

#Prostate Cancer #Men's Health #AUAUniversity #Health and Well-Being #Podcasting Education #American Urological Association